Omnicell, Inc. (NASDAQ:OMCL) Receives $42.20 Consensus PT from Analysts

Omnicell, Inc. (NASDAQ:OMCL) has been given a consensus rating of “Hold” by the six research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $42.20.

A number of research firms have commented on OMCL. Benchmark reaffirmed a “buy” rating and set a $38.00 price objective on shares of Omnicell in a research report on Tuesday, April 30th. Wells Fargo & Company reduced their target price on shares of Omnicell from $28.00 to $26.00 and set an “equal weight” rating for the company in a report on Friday, February 9th.

Omnicell Stock Performance

Shares of NASDAQ OMCL opened at $32.24 on Friday. The company has a current ratio of 2.38, a quick ratio of 2.13 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $1.48 billion, a P/E ratio of -70.09, a P/E/G ratio of 139.11 and a beta of 0.77. Omnicell has a 12 month low of $25.69 and a 12 month high of $77.14. The stock has a 50 day moving average of $28.59 and a 200-day moving average of $31.23.

Institutional Trading of Omnicell

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Covestor Ltd grew its position in shares of Omnicell by 65.6% during the 3rd quarter. Covestor Ltd now owns 1,355 shares of the company’s stock worth $61,000 after purchasing an additional 537 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of Omnicell in the third quarter valued at approximately $62,000. Neo Ivy Capital Management acquired a new stake in Omnicell during the third quarter worth approximately $78,000. Fifth Third Bancorp increased its stake in Omnicell by 143.2% during the 3rd quarter. Fifth Third Bancorp now owns 2,230 shares of the company’s stock worth $100,000 after acquiring an additional 1,313 shares during the period. Finally, EntryPoint Capital LLC raised its holdings in Omnicell by 121.2% in the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after acquiring an additional 1,345 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.